CBDV cannabinoid, also known as cannabidivarin, is one of several compounds originating from cannabis and hemp plants. These compounds, known as cannabinoids, are partly responsible for cannabis’s numerous impacts and therapeutic benefits.
CBDV shares structural similarities with CBD (cannabidiol). CBDV, like CBD, is not psychoactive when isolated, and so does not provide the euphoric feeling associated with high-THC weed.
CBDV has been detected mostly in C. indica landrace strains imported from Asia and Africa, as well as cultivars inherently lower in THC. CBDV levels are often higher in strains that are strong in CBD.
CBDV’s Potential Medical Benefits
Much of the CBDV cannabinoid research has focused on its influence on seizures. GW Pharmaceuticals, which produced the first FDA-approved CBD medicine, Epidiolex, is currently working on GPW42006, a CBDV-based drug to lessen or prevent epileptic and other types of seizures.
Their findings indicate that CBDV cannabinoid impacts the neurochemical route of capsaicin receptors, which is involved in both the start and progression of numerous kinds of epilepsy. CBDV has been demonstrated to be anti-epileptic “across a spectrum of in vitro and in vivo types of epilepsy,” according to GW.
CBDV is also looking promising in a number of other medical fields:
CBDV has shown potential in treating the neurobehavioral difficulties linked with Rett syndrome, according to a 2018 mouse study. An X chromosomal mutation causes Rett syndrome, which affects girls and causes seizures, speech problems, and muscle rigidity. CBDV appears to benefit both genetically determined and chemically generated versions of this and comparable disorders.
CBDV cannabinoid was discovered to repair memory deficits in mice with the same genetic abnormality as persons with Rett syndrome in a 2019 animal study published in the Journal of Psychopharmacology. CBDV also assisted with neurological issues, but the results were very temporary.
CBDV was discovered to potentially aid patients with Duchenne muscular dystrophy in a similar 2019 study published inside the British Journal of Pharmacology (DMD). Chronic inflammation and permanent skeletal muscle injury and degeneration define this condition. CBDV has the potential to decrease inflammation while also restoring and potentially improving muscular function. CBDV also improved mobility, indicating that the molecule has the potential to be a therapeutic therapy for DMD.
Childhood intractable epilepsy & autism spectrum disorder (ASD) frequently coexist. CBDV cannabinoid is being studied as a possible treatment for some of the more serious ASD symptoms, such as repeated behavioral issues, cognitive difficulty, and communication and social functioning deficits.
CBDV cannabinoid may possibly have anti-nausea properties. CBDV appears to function as an agonist to the CB1 receptors in rodents, hence inhibiting the nausea response.
Despite the fact that CBDV was found 50 years ago, significant study is only now beginning. With GW Pharmaceuticals’ CBDV clinical trials already ongoing, this is a promising start to uncovering the secrets of some other potentially strong cannabinoid.
At The Bottom Line
Despite the fact that researchers have known about CBDV for some period, clinical investigations are currently ongoing. More study could expand CDBV’s potential, but for now, data suggests CBV could be effective for treating ASD. If CBDV is approved as a medicine, further information about its effects will be available.
